GlassScriptPhysician profile
Marilu Colon
NPI 1295842862
$11,520.67
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,466 · 2020: $2,211 · 2021: $2,393 · 2022: $1,614 · 2023: $2,594 · 2024: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278 · Travel and Lodging: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.66 |
| Travel and Lodging | $559.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,662.14 | 2019-2023 | Simponi Aria, Tremfya |
| Amgen INC. | $1,581.26 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,122.09 | 2019-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $926.13 | 2019-2023 | |
| Abbvie INC. | $898.82 | 2019-2024 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $782.17 | 2019-2023 | Krystexxa |
| Bioventus LLC | $639.90 | 2021-2024 | Stimrouter Implantable Kit, Exogen Ultrasound Bone Healing System |
| Glaxosmithkline, LLC. | $462.08 | 2019-2023 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $451.00 | 2021-2024 | Saphnelo |
| Radius Health, INC. | $421.24 | 2019-2023 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $397.77 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $358.91 | 2020-2024 | Acthar |
| Pfizer INC. | $282.90 | 2019-2023 | |
| Celgene Corporation | $237.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.14 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilu Colon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.